- Trinity Biotech's haemostasis business
SummaryDiagnostica Stago SAS - proposed acquisition of Trinity Biotech's haemostasis business
Market definitionIt was not considered necessary to form a definitive view on the relevant market definition. However, the acquisition was considered in relation to the Australian market for haemostasis reagents and instruments.
Competition analysisIt was considered that the proposed acquisition would be unlikely to result in a substantial lessening of competition in any market, including because it appears:
- the merged firm is likely to continue to face strong competition from substitute suppliers, notably Siemens Healthcare Diagnostics and Beckman Coulter; and
- the proposed acquisition is unlikely to result in the removal of a vigorous and effective competitor.
|15/03/2010||ACCC commenced a review under the Merger Review Process Guidelines.|
|26/03/2010||Closing date for submissions from interested parties.|
|01/04/2010||ACCC announced it would not oppose the proposed acquisition.|